istock-896469402-stuart-ritchie

Stuart Ritchie / iStockphoto.com

30 August 2018Americas

FDA warns 21 websites over misbranded opioid drugs

The US Food and Drug Administration (FDA) has warned 21 websites over the illegal marketing of misbranded versions of opioid medications.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Emergent BioSolutions to buy Adapt Pharma for $735m

30 August 2018 Life sciences company Emergent BioSolutions announced plans to acquire Adapt Pharma earlier this week, in what the company said was an effort to combat the public health threat from opioid overdose.

FDA and DEA warn over sale of misbranded opioid drugs

1 October 2019 The US Food and Drug Administration and Drug Enforcement Administration have issued joint warning letters to four online networks which allegedly sell unapproved and misbranded versions of medicines.

More on this story

Emergent BioSolutions to buy Adapt Pharma for $735m

30 August 2018 Life sciences company Emergent BioSolutions announced plans to acquire Adapt Pharma earlier this week, in what the company said was an effort to combat the public health threat from opioid overdose.

FDA and DEA warn over sale of misbranded opioid drugs

1 October 2019 The US Food and Drug Administration and Drug Enforcement Administration have issued joint warning letters to four online networks which allegedly sell unapproved and misbranded versions of medicines.

More on this story

Emergent BioSolutions to buy Adapt Pharma for $735m

30 August 2018 Life sciences company Emergent BioSolutions announced plans to acquire Adapt Pharma earlier this week, in what the company said was an effort to combat the public health threat from opioid overdose.

FDA and DEA warn over sale of misbranded opioid drugs

1 October 2019 The US Food and Drug Administration and Drug Enforcement Administration have issued joint warning letters to four online networks which allegedly sell unapproved and misbranded versions of medicines.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent